JP2004531263A5 - - Google Patents

Info

Publication number

JP2004531263A5

JP2004531263A5 JP2002589639A JP2002589639A JP2004531263A5 JP 2004531263 A5 JP2004531263 A5 JP 2004531263A5 JP 2002589639 A JP2002589639 A JP 2002589639A JP 2002589639 A JP2002589639 A JP 2002589639A JP 2004531263 A5 JP2004531263 A5 JP 2004531263A5

Authority

JP

Japan

Prior art keywords

specific binding

binding member

egfr

cells

seq

Prior art date

2002-05-13

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 230000009870 specific binding Effects 0.000 claims 41
• 210000004027 cell Anatomy 0.000 claims 19
• 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 19
• 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 19
• YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 19
• 230000027455 binding Effects 0.000 claims 18
• 206010028980 Neoplasm Diseases 0.000 claims 14
• 108091028043 Nucleic acid sequence Proteins 0.000 claims 13
• 238000000034 method Methods 0.000 claims 11
• 239000000203 mixture Substances 0.000 claims 11
• 108090000765 processed proteins & peptides Proteins 0.000 claims 9
• 108020004707 nucleic acids Proteins 0.000 claims 8
• 102000039446 nucleic acids Human genes 0.000 claims 8
• 150000007523 nucleic acids Chemical class 0.000 claims 8
• 201000011510 cancer Diseases 0.000 claims 7
• 229920001184 polypeptide Polymers 0.000 claims 7
• 102000004196 processed proteins & peptides Human genes 0.000 claims 7
• 125000003275 alpha amino acid group Chemical group 0.000 claims 6
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 5
• 241000124008 Mammalia Species 0.000 claims 4
• 239000002246 antineoplastic agent Substances 0.000 claims 4
• 229940127089 cytotoxic agent Drugs 0.000 claims 3
• 238000001514 detection method Methods 0.000 claims 3
• 239000003112 inhibitor Substances 0.000 claims 3
• WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims 2
• 241001465754 Metazoa Species 0.000 claims 2
• 230000002159 abnormal effect Effects 0.000 claims 2
• 239000008280 blood Substances 0.000 claims 2
• 210000004369 blood Anatomy 0.000 claims 2
• 239000002552 dosage form Substances 0.000 claims 2
• 230000000694 effects Effects 0.000 claims 2
• 239000012634 fragment Substances 0.000 claims 2
• 230000013595 glycosylation Effects 0.000 claims 2
• 238000006206 glycosylation reaction Methods 0.000 claims 2
• 230000004807 localization Effects 0.000 claims 2
• 230000001613 neoplastic effect Effects 0.000 claims 2
• 239000008194 pharmaceutical composition Substances 0.000 claims 2
• 230000002285 radioactive effect Effects 0.000 claims 2
• 238000011363 radioimmunotherapy Methods 0.000 claims 2
• 239000000523 sample Substances 0.000 claims 2
• 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 2
• 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 2
• NHFDRBXTEDBWCZ-ZROIWOOFSA-N 3-[2,4-dimethyl-5-[(z)-(2-oxo-1h-indol-3-ylidene)methyl]-1h-pyrrol-3-yl]propanoic acid Chemical compound OC(=O)CCC1=C(C)NC(\C=C/2C3=CC=CC=C3NC\2=O)=C1C NHFDRBXTEDBWCZ-ZROIWOOFSA-N 0.000 claims 1
• 208000022211 Arteriovenous Malformations Diseases 0.000 claims 1
• 206010003571 Astrocytoma Diseases 0.000 claims 1
• 241000193830 Bacillus <bacterium> Species 0.000 claims 1
• 101100348617 Candida albicans (strain SC5314 / ATCC MYA-2876) NIK1 gene Proteins 0.000 claims 1
• 108091026890 Coding region Proteins 0.000 claims 1
• 102000053602 DNA Human genes 0.000 claims 1
• 241000588724 Escherichia coli Species 0.000 claims 1
• 102000003886 Glycoproteins Human genes 0.000 claims 1
• 108090000288 Glycoproteins Proteins 0.000 claims 1
• 241000238631 Hexapoda Species 0.000 claims 1
• 208000000172 Medulloblastoma Diseases 0.000 claims 1
• 241000589516 Pseudomonas Species 0.000 claims 1
• 108020004511 Recombinant DNA Proteins 0.000 claims 1
• 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
• 101100007329 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS1 gene Proteins 0.000 claims 1
• 101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 claims 1
• 241000187747 Streptomyces Species 0.000 claims 1
• 239000002671 adjuvant Substances 0.000 claims 1
• 150000001413 amino acids Chemical class 0.000 claims 1
• 230000002927 anti-mitotic effect Effects 0.000 claims 1
• 239000000427 antigen Substances 0.000 claims 1
• 102000036639 antigens Human genes 0.000 claims 1
• 108091007433 antigens Proteins 0.000 claims 1
• 230000005744 arteriovenous malformation Effects 0.000 claims 1
• 239000012472 biological sample Substances 0.000 claims 1
• 210000004556 brain Anatomy 0.000 claims 1
• 229940022399 cancer vaccine Drugs 0.000 claims 1
• 238000009566 cancer vaccine Methods 0.000 claims 1
• 230000032823 cell division Effects 0.000 claims 1
• 230000002490 cerebral effect Effects 0.000 claims 1
• 239000003153 chemical reaction reagent Substances 0.000 claims 1
• 239000003795 chemical substances by application Substances 0.000 claims 1
• 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
• 238000003745 diagnosis Methods 0.000 claims 1
• 238000002059 diagnostic imaging Methods 0.000 claims 1
• 239000003085 diluting agent Substances 0.000 claims 1
• 229940079593 drug Drugs 0.000 claims 1
• 239000003814 drug Substances 0.000 claims 1
• AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 1
• 229960001433 erlotinib Drugs 0.000 claims 1
• XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 1
• 229960002584 gefitinib Drugs 0.000 claims 1
• 208000005017 glioblastoma Diseases 0.000 claims 1
• 239000003966 growth inhibitor Substances 0.000 claims 1
• 210000005260 human cell Anatomy 0.000 claims 1
• 238000009396 hybridization Methods 0.000 claims 1
• 230000003463 hyperproliferative effect Effects 0.000 claims 1
• KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 1
• 229960002411 imatinib Drugs 0.000 claims 1
• 206010027191 meningioma Diseases 0.000 claims 1
• 201000011682 nervous system cancer Diseases 0.000 claims 1
• 210000000056 organ Anatomy 0.000 claims 1
• 229960001972 panitumumab Drugs 0.000 claims 1
• 230000026731 phosphorylation Effects 0.000 claims 1
• 238000006366 phosphorylation reaction Methods 0.000 claims 1
• 230000001323 posttranslational effect Effects 0.000 claims 1
• 230000002265 prevention Effects 0.000 claims 1
• 102000004169 proteins and genes Human genes 0.000 claims 1
• 108090000623 proteins and genes Proteins 0.000 claims 1
• 230000000717 retained effect Effects 0.000 claims 1
• 230000019491 signal transduction Effects 0.000 claims 1
• 238000006467 substitution reaction Methods 0.000 claims 1
• 231100000588 tumorigenic Toxicity 0.000 claims 1
• 230000000381 tumorigenic effect Effects 0.000 claims 1
• 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 1
• GFNNBHLJANVSQV-UHFFFAOYSA-N tyrphostin AG 1478 Chemical group C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=CC(Cl)=C1 GFNNBHLJANVSQV-UHFFFAOYSA-N 0.000 claims 1